Kornimate/medical-research-clean huggingface dataset:
anxiety and depression in patients with obstructive sleep apnoea before and after continuous positive airway pressure

Conditions: Obstructive Sleep Apnea

Summary: continuous positive airway pressure (cpap) is the gold-standard treatment for obstructive sleep apnoea (osa), the most common sleep-disordered breathing in the overall population. cpap has shown to be effective in reducing apnoea-hypopnoea index (ahi) as well as other osa polysomnographic outcomes. however, the effectiveness of this device on osa daily functioning and mood disturbances outcomes still remains unclear. the adiposa study is aimed at determining the effects of three-month cpap use on anxiety-depression symptoms in patients with osa. participants will be adults previously diagnosed with osa who will be allocated to a cpap-treatment group. outcomes will be measured at baseline and intervention end-point (three months) including daytime sleepiness, daily functioning and mood (anxiety and depression symptoms), ahi, other neurophysical and cardiorespiratory polysomnographic outcomes, and body weight. adiposa may serve to establish the effectiveness of cpap on daytime functioning and mood disturbances commonly found on patients with osa and, in turn, on other osa outcomes related to anxiety-depression symptoms.


Eligibility criteria:
inclusion criteria: * previous clinical diagnosis of mild/moderate/severe osa (ahi \> 5) by a healthcare professional * use of cpap * motivation to participate in the study * willing to provide informed consent exclusion criteria: * presence of any other primary sleep disorder * presence of any mental disorder (including depression, anxiety, and addiction to alcohol or other substances) * presence of any other severe organic disease, except for those comorbid to osa

Keywords: obstructive sleep apnea
in home hospital care program

Conditions: Common Acute Problems

Summary: to assess the hypothesis that in home hospital care (ihhc) is as safe and effective, less burdensome to families, and less expensive for care of common acute pediatric problems now managed with hospitalization.

a randomized trial compared health care systems with and without ihhc. eligible children presented to the emergency department of our medical center, had common acute problems, and were considered for hospital admission. physicians decided disposition from the emergency department. note that subjects were not randomized directly to ihhc but to a system of care that either included ihhc or did not. to allow best use of scarce home nursing resources, we used a disproportionate selection favoring the system with ihhc. quality measures included adverse events, parent anxiety and satisfaction with care, family disruption, and perceived child health.

Eligibility criteria:
inclusion criteria: randomized from acute care clients presenting in emergency department to ihhc exclusion criteria: randomized from acute care clients presenting in emergency department to inpatient hospital care.

Keywords: acute home care
contrast enhanced ultrasonography (ceus) of patients with crohn's disease

Conditions: Crohn's Disease

Summary: the purpose of this study is investigate if high frequency sonography and contrast enhanced sonography can be used to predict remission in patients with deterioration of crohn's disease treated with steroids or tumor necrosis factor (tnf) alfa inhibitors.


Eligibility criteria:
inclusion criteria: * deterioration of crohn's disease * cdai\>150 * treated with systemic steroids or tnf alfa inhibitors * lesion found on ultrasound exclusion criteria: * disease location not reachable with ileocolonoscopy * pregnancy * acute coronary disease * unstable coronary disease * previous allergic reaction to sonovue or its components

Keywords: crohn's disease sonography contrast enhanced ultrasound
effectiveness of a physical recovery program for head and neck cancer patients (3c-cuidate)

Conditions: Head and Neck Cancer; Pain; Dysfunction

Summary: people receiving a head and neck cancer treatment often do not find an adequate therapeutic response for the side effects derived from this treatment. the objective of this study is to assess the effectiveness of a physical recovery program based on manual therapy over these problems. previous studies have shown the effectiveness of this type of programs on patients who have had cancer in other locations with clinically relevant results. there is a shortage of proposals for this subgroup of patients that require special attention. this project intends to carry out an experimental randomized controlled study with 84 patients treated of head and neck cancer who will be assigned randomly to the study groups: a) manual therapy program or, b) control group. the assessment refers to a baseline form (at the beginning of the study), at 6 weeks and at 6 months of patient follow-up.

manual therapy program consists of 3 sessions a week during 6 weeks, with a total of 18 appointments. measurements are done before starting, after the last intervention and 6 months after finishing the treatment.

Eligibility criteria:
inclusion criteria: * to have ended their treatment in the previous 6-24 months * to have no metastasis or active cancer * to have cervical and/or temporomandibular joint pain \>3 in a visual analogue scale exclusion criteria: * mental or physical illness preventing subjects from participating in the study * previous chronic pain conditions * previous cervical or temporomandibular joint pain * previous dysphagia disorders

Keywords: pain function quality of life head and neck cancer
a study of lcar-aio in subjects with relapsed/refractory autoimmune diseases

Conditions: Relapsed/Refractory Autoimmune Diseases

Summary: this is a prospective, single-arm, open-label, dose-exploration and expansion clinical study of lcar-aio in adult subjects with relapsed/refractory autoimmune diseases.

this is a prospective, single-arm, open-label exploratory clinical study to evaluate the safety, tolerability, pharmacokinetics and efficacy profiles of lcar-aio, a chimeric antigen receptor (car) -t cell therapy in subjects with relapsed/refractory autoimmune diseases. patients who meet the eligibility criteria will receive lcar-aio infusion. the study will include the following sequential stages: screening, apheresis, pre-treatment (cell product preparation: lymphodepleting chemotherapy), treatment (lcar aio infusion) and follow-up.

Eligibility criteria:
inclusion criteria: 1. subjects voluntarily participate in clinical research. 2. age 18-65 years. 3. adequate organ function at screening. 4. clinical laboratory values meet criteria at screening. sle: * have been diagnosed of sle at least 6 months before screening. * at screening, antinuclear antibody, and/or anti-dsdna antibody, and/or anti-smith antibody should be positive. * fulfill relapsed/refractory sle conditions. aav: * have been diagnosed of aav before screening. * positive test for anti-pr3 or anti-mpo antibodies at screening. * fulfill relapsed/refractory aav conditions. ssc: * have been diagnosed of ssc before screening. * at screening, mrss is higher than 10. * fulfill relapsed/refractory ssc conditions. iim: * have been diagnosed of iim before screening. * positive test for myositis-associated antibodies or myositis-specific antibodies at screening. * fulfill relapsed/refractory iim conditions. exclusion criteria: 1. active infections such as hepatitis and tuberculosis. 2. other autoimmune diseases. 3. serious underlying diseases such as tumor, uncontrolled diabetes. 4. female subjects who were pregnant, breastfeeding, or planning to become pregnant while participating in this study or within 1 year of receiving lcar-aio treatment. 5. participated in other clinical trials within 4 weeks.

Keywords: relapsed/refractory systemic lupus erythematosus (r/r sle) relapsed/refractory systemic sclerosis (ssc) ), relapsed/refractory anti-neutrophil cytoplastic antibodies (anca)-associated vasculitis (aav) idiopathic relapsed/refractory inflammatory myopathies (iim)
study of tnferade™ gene therapy, radiation, 5-fu and cisplatin in esophageal cancer

Conditions: Esophageal Cancer

Summary: the primary purpose of this study is to assess the safety and feasibility of giving tnferade™ with 5-fu, cisplatin and radiation therapy to patients with locally advanced, esophageal cancer prior to surgical resection. tnferade™ is a replication deficient (e1, e3 and e4 deleted) adenovirus vector containing the gene for tnf-alpha controlled by a radiation inducible promoter. this allows the expression of tnf-alpha to be greatest in the area receiving radiation. tnf-alpha is a potent cytokine that has been shown to have potent anti-cancer activities but, due to systemic toxicity, could not be delivered at effective doses. tnferade™ is a novel way of selective delivery of tnf-alpha to tumor cells. tnferade™ will be delivered once a week for five weeks by direct intratumoral injection by using endoscopy or endoscopic ultrasound. 5-fu (1000 mg/m2/day) will be delivered via continuous infusion for 96 hours during weeks 1 and 4. cisplatin (75 mg/m2) will be delivered on day 1 and day 29 intravenously. the dose of radiation delivered will be 45 gy in 1.8 gy fractions for 5 weeks.


Eligibility criteria:
inclusion criteria: * 18-75 years for age; * patients with biopsy proven locally advanced adenocarcinoma or squamous cell carcinoma of the esophagus, stage ii, iii, who have not received previous treatment and are considered to have resectable carcinoma; * informed consent; * karnofsky performance status ≥ 70%; * life expectancy greater than 6 months. exclusion criteria: * diagnosis of lymphoma of the esophagus; * history of other malignancy in the past 2 years except carcinoma in situ of the cervix or bladder, non-melanomatous skin cancer or localized early stage prostate cancer with patients continuously disease-free; * previous chemotherapy or radiation for esophageal cancer or previous radiation therapy to the target field; * t4 disease, metastatic (stage iv) disease or confirmed invasion of the bronchial tree; * extension beyond 2 cm into stomach; * liver enzymes \>2.0 x uln (alt, ast, bilirubin, alkaline phosphatase); * coagulopathy (inr \>1.5, ptt ratio \>1.5); * renal insufficiency (creatinine \>2.0 mg/dl; calculated creatinine clearance \<50 ml/min); * significant anemia (hematocrit \<28% or hemoglobin \<9 g/dl) (may have rbc transfusion), or thrombocytopenia (platelet count \<100,000/μl)l or leukopenia (wbc \<3,000/µl; anc \<1,500 μl); * contraindication to endoscopic or eus-guided delivery including obstructive lesions that can not be dilated to pass endoscope; * clinical evidence of active infection of any type, including hepatitis b or c virus; * due to the embryotoxic effects of chemotherapy, pregnant or lactating women, or men unable or unwilling to practice contraception are excluded; * experimental medications within the last four weeks prior to day 1; * chronic systemic corticosteriod use (orally or parenterally administered); * significant concurrent medical or psychiatric illness as defined by the investigator.
what influences patient outcome in obstructive airway disease?

Conditions: COPD

Summary: the aim of this observational study is to utilise the established record linkage data available in tayside to investigate hospital admissions, exacerbations and mortality in copd.


Eligibility criteria:
inclusion criteria: * data collected through tardis database exclusion criteria: * history of asthma or malignancy. less than 50 years of age
flemish inguinal and femoral hernia prospective registry

Conditions: Inguinal Hernia

Summary: prospective registry. the purpose of this clinical trial will be to measure surgical outcome parameters (e.g. recurrence, chronic pain and other quality indicators) after inguinal hernia repair using patient reported outcome measures (proms) in the short- and long-term.

the primary objective is to investigate moderate to severe chronic pain 1 year after inguinal or femoral hernia repair, defined as numeric rating scale (nrs) ≥ 4, during daily activities. the secondary objectives are: * surgical site occurrence (sso) after 30 days * scope and incidence of pre- and postoperative pain (nrs 0 to 10) * the difference between pre- and postoperative nrs scores (relative nrs score) * presence of pain and impact of pain on daily life activities * satisfaction and quality of life * sexual function * anxiety and depression * catastrophizing * recurrence * development of a predictive model for chronic pain.

Eligibility criteria:
inclusion criteria * consecutively all patients with a groin hernia (inguinal and/or femoral hernia) operated starting 01.01.2018. * male and female * 18 years or older * operated of supervised by a participating surgeon (participating in this study is not necessarily by a whole surgical department of a hospital, but by specific surgeons) * elective and emergency surgery * primary and recurrent hernia * metachronous and synchronous hernia * signed informed consent form exclusion criteria * younger than 18 years * not operated or supervised by participating surgeon * pregnant at inclusion in the registry * no signed informed consent form
phospholipid-rich dairy extract for cognitive function

Conditions: Cognitive Function; Cognitive Decline

Summary: this clinical trial aims to determine whether dietary phospholipid-rich dairy milk extract improves cognitive function in adults with mild cognitive impairment and to assess its safety. the main questions are: * does dietary phospholipid-rich dairy milk extract improve cognitive function in participants? * what side effects occur when participants take phospholipid-rich dairy milk extract?

researchers will compare dietary phospholipid-rich dairy milk extract to a placebo to evaluate their effectiveness in improving cognitive function in participants. participants will: * take dietary phospholipid-rich dairy milk extract or a placebo daily for 12 weeks. * visit the clinic at 1, 2, 6, and 12 weeks for checkups and tests

Eligibility criteria:
inclusion criteria: * age: adults aged 55-85 years (inclusive), both male and female * global deterioration scale (gds) score of 2-3: gds 2: subjective memory impairment without objective evidence gds 3: mild objective memory impairment * absence of dementia according to established diagnostic criteria * ability to read korean exclusion criteria: * severe medical conditions within the past 6 months: history of severe cerebrovascular disease (cerebral infarction, cerebral hemorrhage), cardiac disease (angina, myocardial infarction, heart failure, arrhythmia requiring treatment), or malignancy (note: participants with a history of cerebrovascular or cardiac disease who are clinically stable may be included at the investigator's discretion) * cognitive impairment-associated diseases: dementia, parkinson's disease, cerebral infarction, or other conditions associated with cognitive decline uncontrolled hypertension: blood pressure ≥160/100 mmhg (measured after 10 minutes of rest) * poor glycemic control: fasting blood glucose ≥160 mg/dl in diabetic patients * uncontrolled thyroid dysfunction: currently receiving treatment for uncontrolled hypothyroidism or hyperthyroidism * renal impairment: serum creatinine ≥2 times the upper limit of normal for the institution * hepatic impairment: ast or alt ≥2 times the upper limit of normal for the institution * severe gastrointestinal symptoms: complaints of severe heartburn, dyspepsia, or other gastrointestinal distress * medications affecting cognitive function within the past month: use of drugs (antipsychotics, anti-degenerative agents, cognitive enhancers, tricyclic antidepressants, hormone replacement therapy) or health functional foods that may influence cognitive function due to dementia or other cognitive abnormalities * other clinical trial participation: participation in other drug clinical trials within the past month or planned participation during the study period * alcohol abuse * food allergies: known allergic reactions to study product components * investigator discretion: any other condition deemed inappropriate for study participation by the investigator
dexamethasone with tap block increasing the duration of the peripheral nerve block in caesarian section

Conditions: Pain

Summary: nowadays cesarean sections became the most popular surgery worldwide with the consumption of the hospital resources and the continuous need to decrease the costs, work load and medical stuff engagement. one of the most common problem is the need to control pain post operatively, this issue increase the work load over the pain management team and increase lead to patient in satisfaction. this study will test the usage of dexamethasone with different doses (4 and 8 mg) either locally or intravenously (i.v.) with the local anesthetics in tap (transversus abdominis plane) block to prolong the duration of the block and decrease the need of post-operative analgesics.

nowadays cesarean sections became the most popular surgery worldwide with the consumption of the hospital resources and the continuous need to decrease the costs, work load and medical stuff engagement. one of the most common problem is the need to control pain post operatively, this issue increase the work load over the pain management team and increase lead to patient in satisfaction.(1,2,3) the presence of the adjuvant which can be added to the conventional anesthetic medications can prolong the duration of action and decrease the need for frequent post-operative analgesics.(4,5) the idea of adding a catheter or placing an epidural catheter still have a quite limitation regarding the patients compliance, delayed ambulation and high costs, these limitations redirect the anesthetist again to the use of adjuvant with a single shot block to prolong the duration of it and decrease the need of subsequent analgesics.(6) dexamethasone proved to be an effective adjuvant in prolongation of the nerve blocks with the question regarding the proper route and dose (7,8,9,10). this study will test the usage of dexamethasone with different doses (4 and 8 mg) either locally or intravenously (i.v.) with the local anesthetics in tap (transversus abdominis plane) block to prolong the duration of the block and decrease the need of post-operative analgesics.

Eligibility criteria:
inclusion criteria: * any patient asa (american society of anesthesia) i or ii, * aged between 18 and 45 scheduled for elective cesarean section. exclusion criteria: * patient refusal, * age below 18 or above 45 years, * coagulopathy with inr (international normalized ratio) more than 1.5 or platelets below 100000, * uncontrolled diabetes, uncontrolled hypertensive, addict patient, * psychological instability, and * allergy to the used drugs, * failure of spinal, * conversion to general of anesthesia, * failure of application of tap block.
comparision among classifications for acute diverticulitis: a multicenter study

Conditions: Acute Diverticulitis

Summary: even though hinchey classification requires operative intervention, yet remains the established and most universally used scoring system for acute diverticulitis. several other classifications have been described. the american association for the surgery of trauma (aast) developed a severity scale for surgical conditions, including diverticulitis. the same was done by the world society of emergency surgery, that proposed a specific classification mainly based on the ct scan findings. this is a pilot study to compare the aast and wses classifications for acute colonic diverticulitis with the traditional hinchey classification. we hypothesize that all the classifications are equivalent one each other in predicting outcomes


Eligibility criteria:
inclusion criteria: * acute colonic diverticulitis exclusion criteria: * other severe conditions of end-life
short life agents in balanced anesthesia on obstructive sleep apnea syndrome

Conditions: Sleep Apnea Syndromes; Sleep Apnea, Obstructive

Summary: the investigators aim to assess the respiratory effect of short half-life agents in balanced anesthesia on patients suffering from non-treated or suspected obstructive sleep apnea syndrome (osa) we will study the impact on osa of a regimen of remifentanil-desflurane versus a regimen of fentanyl-sevoflurane. each patient will undergo three respiratory portable polygraphies: the night before the surgery ; the first night following the surgery ; the third night following the surgery.


Eligibility criteria:
inclusion criteria: * physical status i - iii * patient scheduled to undergo lower limb orthopedic surgery * patients known for non-treated obstructive sleep apnea or suspected of having an obstructive sleep apnea exclusion criteria: * patients known for treated obstructive sleep apnea ; * severe respiratory disease (i.e., chronic obstructive pulmonary disease, asthma, pulmonary fibrosis); * severe cardiovascular disease * chronic use of opiates ≥ 30mg/j morphine eq. * chronic use of benzodiazepine * inability to consent * refusal
remifentanil requirement for acceptable intubating condition

Conditions: Intubating Condition

Summary: ketamine and opioid are known to improve the intubating condition, respectively. combination of ketamine and opioid potentiate analgesic effect and give hemodynamic stability in complementary manner. therefore, the combination use of ketamine and remifentanil could be useful for acceptable intubating condition in the general anesthesia without the use of neuromuscular blocking agent. generally, induction dose of ketamine ranges between 1 and 2 mg. there was no report about the optimal dose of remifentanil with 1 or 2 mg ketamine induction dose for intubation without neuromuscular blocking agent. the investigators focus on remifentanil dose using dixon's up and down method.


Eligibility criteria:
inclusion criteria: * asa i-ii * undergoing general anesthesia with endotracheal tube exclusion criteria: * anticipated difficult airway * patient with upper respiratory infection within 14 days * asthma
thereapeutic recommendantion for children with a hodgkin lymphoma

Conditions: Staging; Therapeutic Recommendations

Summary: the gfaop propose a simple and reproducible staging according to clinical, biological and radiological data. develop standardized but different therapeutic recommendations based on the availability or lack of radiation therapy in the pilot unites who will adapt these recommendations.

in high-income countries, therapeutic outcomes exceed 90% and therapeutic de-escalation is necessary to reduce mainly the effects of long-term radiotherapy. within the same country, there are also differences between the therapeutic protocols used in the different centres. the experience of sub-saharan african units of the franco-african paediatric oncology group (gfaop) in the treatment of pediatric hodgkin lymphoma in 104 patients was based on chemotherapy alone. the latter was based on copp/abv cures without complementary irradiation adapted to the initial stratification and modulated according to the morphological response. overall survival at 5 years was 82% at 30 months after a median decrease of 17 months. it seemed appropriate to bring together in a single committee the representatives of the various pilot units in order to standardize the therapeutic protocols in the african countries. so with this recommendation the gfaop propose a simple and reproducible staging according to clinical, biological and radiological data. - develop standardized but different therapeutic recommendations based on the availability or lack of radiation therapy in the pilot unit.

Eligibility criteria:
inclusion criteria: under 18 years of age at diagnosis * suffering from "classical" hodgkin's disease according to the who classification. * with no history of hematological malignancies or constitutional or acquired immune deficiencies exclusion criteria: * over 18 years of age at diagnosis * a history of hematological malignancies or a history of constitutional or a history of acquired immune deficiencies